Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    15070920 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly
Condition: Acromegaly
Intervention: Drug: Octreotide-LAR

Indicates status has not been verified in more than two years